NASDAQ:PHVS Pharvaris (PHVS) Stock Price, News & Analysis $31.68 +0.56 (+1.80%) Closing price 10/7/2026 04:00 PM EasternExtended Trading$31.66 -0.02 (-0.05%) As of 10/7/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Pharvaris Stock (NASDAQ:PHVS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pharvaris alerts:Sign Up Key Stats Today's Range$30.58▼$32.3250-Day Range$30.49▼$38.8652-Week Range$20.65▼$43.25Volume341,842 shsAverage Volume891,690 shsMarket Capitalization$2.07 billionP/E RatioN/ADividend YieldN/APrice Target$58.60Consensus RatingModerate Buy Company Overview Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways. The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121. Pharvaris is evaluating deucrictibant in immediate-release and extended-release formulations for the on-demand treatment and prevention of HAE attacks. The company’s development strategy is intended to provide convenient oral alternatives to injectable or infused therapies. Pharvaris was founded by individuals with experience in HAE drug development and has operations in Europe and the United States. The company is advancing its pipeline through international clinical development programs and became a publicly traded company in 2021. Its headquarters are in Zug, Switzerland.AI Generated. May Contain Errors. Read More Pharvaris Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScorePHVS MarketRank™: Pharvaris scored higher than 84% of companies evaluated by MarketBeat, and ranked 84th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPharvaris has a consensus price target of $58.60, representing about 85.0% upside from its current price of $31.68.Amount of Analyst CoveragePharvaris has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pharvaris' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pharvaris are expected to grow in the coming year, from ($3.12) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -10.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -10.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 6.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pharvaris' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.10% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 1.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharvaris has recently decreased by 17.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.26 News SentimentPharvaris has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Pharvaris this week, compared to 6 articles on an average week.Search Interest11 people have searched for PHVS on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat Follows7 people have added Pharvaris to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,643,666.00 in company stock.Percentage Held by Insiders11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsPharvaris has minimal institutional ownership at this time.Read more about Pharvaris' insider trading history. Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHVS Stock News HeadlinesPharvaris Stock Gets Weaker EPS Estimate from HC WainwrightOctober 7 at 8:01 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB) and Pharvaris (PHVS)October 7 at 6:45 AM | theglobeandmail.comAnthropic’s $40 million midterm moveAnthropic, creator of Claude, has committed $40 million to Public First Action, a nonpartisan group advocating AI safeguards, American leadership, and transparency ahead of the midterms. Alexander Green, Chief Investment Strategist of The Oxford Club, says the move signals Anthropic's shift from a technical story to a political and financial force, especially as IPO talk builds. A publicly accessible vehicle lists Anthropic as its largest holding, alongside Databricks and Anduril, and can be purchased through an ordinary brokerage account. | The Oxford Club (Ad)Pharvaris Study Shows HAE Patients Prefer Oral Prophylaxis Over InjectionsOctober 5 at 10:08 PM | rttnews.comPharvaris (NASDAQ:PHVS) Director Sells $28,952.00 in StockSeptember 25, 2026 | insidertrades.comPharvaris (NASDAQ:PHVS) CFO David Nassif Sells 6,000 Shares of StockSeptember 24, 2026 | insidertrades.comRobert Glassman Sells 14,493 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 22, 2026 | insidertrades.comRobert Glassman Sells 8,667 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 18, 2026 | insidertrades.comSee More Headlines PHVS Stock Analysis - Frequently Asked Questions How have PHVS shares performed this year? Pharvaris' stock was trading at $27.75 at the start of the year. Since then, PHVS shares have increased by 14.2% and is now trading at $31.68. How were Pharvaris' earnings last quarter? Pharvaris N.V. (NASDAQ:PHVS) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.06. When did Pharvaris IPO? Pharvaris (PHVS) raised $149 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,270,500 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharvaris own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharvaris investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), Jabil (JBL), Disc Medicine (IRON) and Adobe (ADBE). Company Calendar Last Earnings8/12/2026Today10/07/20263rd Annual Guggenheim Healthcare Innovation Conference11/09/2026Next Earnings (Estimated)11/11/20269th Annual Evercore ISI HealthCONx Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PHVS's financial health is in the Green zone, according to TradeSmith. PHVS has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PHVS CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees148Year Founded2015Price Target and Rating Average Price Target for Pharvaris$58.60 High Price Target$79.00 Low Price Target$30.00 Potential Upside/Downside+85.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-61.40% Return on Assets-56.00% Debt Debt-to-Equity RatioN/A Current Ratio11.94 Quick Ratio11.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book6.73Miscellaneous Outstanding Shares65,410,000Free Float57,664,000Market Cap$2.07 billion OptionableNot Optionable Beta-2.46 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:PHVS) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersWhat Could Change After November 3rd?Democrats are favored to take the House on November 3rd, needing just five seats to flip the chamber. The last...USA Capital Gold | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredChina ATTACK on American Dollar set for 11/12/2026A former Wall Street Journal personal finance expert warns China may be setting the stage for a major move aga...International Living | SponsoredA dividend every week of the yearMost dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering ...Market Savvy | Sponsored“Whoever wins AI, wins”Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
